Sarah Romano - 10 Feb 2022 Form 4 Insider Report for KIORA PHARMACEUTICALS INC (KPRX)

Reporting relationship: Chief Financial Officer
Issuer ticker: KPRX
Reported as of: 10 Feb 2022
Net transaction value: -$74.52
SEC form: 4
Accepted by SEC: 11 Feb 2022, 15:31:07 UTC
Prior SEC filing: 03 Feb 2022
Next SEC filing: 02 Mar 2022
Source filing: View source filing
Reporting owner signature: /s/ Sarah Romano

Key filing fact

Sarah Romano filed Form 4 for KIORA PHARMACEUTICALS INC (KPRX) on 11 Feb 2022.

Key facts

This page summarizes Sarah Romano's Form 4 filing for KIORA PHARMACEUTICALS INC (KPRX).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 11 Feb 2022, 15:31.

Change

Previous filing in this sequence was filed on 03 Feb 2022.
Current net transaction value: -$74.52.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

KPRX transaction

Common Stock

Tax liability

Transaction value: $74.52
Shares: -108
Change %: -0.47%
Price: $0.6900
Shares after: 22,746
Date: 10 Feb 2022
Ownership: Direct
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Sale of shares to cover taxes due on restricted stock that vested on 02/01/2022.

Footnote F2

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.69 to $0.70, inclusive. The reporting person hereby undertakes to provide to Kiora Pharmaceuticals, Inc., any security holder of Kiora Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.